Arno Fritsch

4.3k total citations · 2 hit papers
38 papers, 2.9k citations indexed

About

Arno Fritsch is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Statistics and Probability. According to data from OpenAlex, Arno Fritsch has authored 38 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 13 papers in Cardiology and Cardiovascular Medicine and 6 papers in Statistics and Probability. Recurrent topics in Arno Fritsch's work include Pulmonary Hypertension Research and Treatments (27 papers), Cardiovascular Issues in Pregnancy (8 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Arno Fritsch is often cited by papers focused on Pulmonary Hypertension Research and Treatments (27 papers), Cardiovascular Issues in Pregnancy (8 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Arno Fritsch collaborates with scholars based in Germany, United States and France. Arno Fritsch's co-authors include Hossein Ardeschir Ghofrani, Friedrich Grimminger, D. Neuser, Pavel Jansa, Marc Humbert, Ekkehard Grünig, David Langleben, Zhi‐Cheng Jing, Marius M. Hoeper and Eckhard Mayer and has published in prestigious journals such as New England Journal of Medicine, Bioinformatics and Cancer.

In The Last Decade

Arno Fritsch

37 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Riociguat for the Treatment of Pulmonary Arterial Hypertension

2013 944 citations Hossein Ardeschir Ghofrani, Nazzareno Galiè et al. New England Journal of Medicine profile →
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

2013 911 citations Hossein Ardeschir Ghofrani, Andrea Maria D’Armini et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Arno Fritsch

Since Specialization

Citations

This map shows the geographic impact of Arno Fritsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arno Fritsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arno Fritsch more than expected).

Fields of papers citing papers by Arno Fritsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arno Fritsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arno Fritsch. The network helps show where Arno Fritsch may publish in the future.

Co-authorship network of co-authors of Arno Fritsch

This figure shows the co-authorship network connecting the top 25 collaborators of Arno Fritsch. A scholar is included among the top collaborators of Arno Fritsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arno Fritsch. Arno Fritsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·Martin Reck, Leora Horn, Silvia Novello, Fabrice Barlési, István Albert, Erzsébet Juhász, Dariusz M. Kowalski, G. Robinet, Jacques Cadranel, Paolo Bidoli, John Chung, Arno Fritsch, (unknown), Thierry André, Ramaswamy Govindan	50
2	Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC) 2016 ·Annals of Oncology ·Martin Reck, Leora Horn, Silvia Novello, Fabrice Barlési, István Albert, Erzsébet Juhász, (unknown), Arno Fritsch, (unknown), Mark Rutstein, (unknown), Ramaswamy Govindan	4
3	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) 2015 ·European Respiratory Journal ·Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, (unknown), Neil Davie, Hossein Ardeschir Ghofrani	151
4	General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials 2015 ·Journal of Biopharmaceutical Statistics ·Alex Dmitrienko, (unknown), Arno Fritsch, Ilya Lipkovich	28
5	Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension 2014 ·CHEST Journal ·Chen Wang, Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Gérald Simonneau, Adam Torbicki, Martin R. Wilkins, Arno Fritsch, Neil Davie, Eckhard Mayer	4
6	Late-breaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension 2014 ·European Respiratory Journal ·Gérald Simonneau, Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado, Eckhard Mayer	7
7	Late-breaking abstract: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension 2014 ·European Respiratory Journal ·Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, (unknown), Neil Davie, Hossein Ardeschir Ghofrani	10
8	Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) 2014 ·European Respiratory Journal ·Eckhard Mayer, Andrzej Biederman, Andrea Maria D’Armini, Ekkehard Grünig, Pavel Jansa, David P. Jenkins, Nick H. Kim, Walter Klepetko, Jaroslav Lindner, Michael M. Madani, Chen Wang, Neil Davie, Arno Fritsch, Hossein Ardeschir Ghofrani	1
9	Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension 2014 ·CHEST Journal ·(unknown), Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Lewis J. Rubin, Arno Fritsch, Neil Davie, Hossein Ardeschir Ghofrani	3
10	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) 2014 ·European Respiratory Journal ·Gérald Simonneau, Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Pablo Colorado, Eckhard Mayer	222
11	Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study 2013 ·European Respiratory Journal ·Ekkehard Grünig, Nazzareno Galiè, Marc Humbert, Anne Keogh, David Langleben, Lewis J. Rubin, Rudolf Speich, Arno Fritsch, Neil Davie, Hossein Ardeschir Ghofrani	1
12	Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study 2013 ·European Respiratory Journal ·Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Lewis J. Rubin, Michael Ochan Kilama, Arno Fritsch, Neil Davie, Hossein Ardeschir Ghofrani	5
13	Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study 2013 ·European Respiratory Journal ·Eckhard Mayer, Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, Ekkehard Grünig, Pavel Jansa, Nick H. Kim, Gérald Simonneau, Adam Torbicki, Chen Wang, Martin R. Wilkins, Neil Davie, Arno Fritsch, Marius M. Hoeper	2
14	Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study 2013 ·European Respiratory Journal ·Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, Nick H. Kim, Eckhard Mayer, Gérald Simonneau, Martin R. Wilkins, Tomás Pulido, Arno Fritsch, Neil Davie, Marius M. Hoeper	1
15	Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) 2013 ·European Respiratory Journal ·Hossein Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Nick H. Kim, Eckhard Mayer, Gérald Simonneau, Mirko Sikirica, Arno Fritsch, Neil Davie, (unknown), Martin R. Wilkins	3
16	Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH) 2013 ·European Respiratory Journal ·Hossein Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, Marc Humbert, Anne Keogh, Lewis J. Rubin, Mirko Sikirica, Arno Fritsch, Neil Davie, Stacie Hudgens, Nicola Bonner, (unknown), David Langleben	1
17	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study 2013 ·CHEST Journal ·(unknown), Andrea Maria D’Armini, Hossein Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick Kim, Chen Wang, Martin R. Wilkins, Arno Fritsch, Neil Davie, Gerrit Weimann, Eckhard Mayer	9
18	Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study 2013 ·CHEST Journal ·Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, (unknown), D. Neuser, Hossein Ardeschir Ghofrani	3
19	Riociguat for the Treatment of Pulmonary Arterial Hypertension breakdown → 2013 ·New England Journal of Medicine ·Hossein Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Michael Ochan Kilama, Arno Fritsch, D. Neuser, Lewis J. Rubin	944
20	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension breakdown → 2013 ·New England Journal of Medicine ·Hossein Ardeschir Ghofrani, Andrea Maria D’Armini, Friedrich Grimminger, Marius M. Hoeper, Pavel Jansa, Nick H. Kim, Eckhard Mayer, Gérald Simonneau, Martin R. Wilkins, Arno Fritsch, D. Neuser, Gerrit Weimann, Chen Wang	911

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact